{
  "issued_date": "2010-02-10", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON071112", 
  "doc_details": {
    "Type": "Medical Device Alert", 
    "Series No": "MDA/2010/012", 
    "Audience": "Healthcare professionals", 
    "Published": "10 February 2010 at 10:00", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "5", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "image/gif", 
      "title": "Teligen implantable cardioverter defibrillator and Cognis cardiac resynchronisation therapy defebrillator manufactured by Boston Scientific", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/idcm2/groups/dts-bs/documents/medicaldevicealert/con071125.gif", 
      "filename": "downloads/27b07e9ab84d834fb59dc5284767292310e2d653/con071125.gif", 
      "original_filename": "con071125.gif"
    }
  ], 
  "body": "## Device\n\nTeligen implantable cardioverter defibrillators (ICDs) and Cognis cardiac resynchronisation therapy defibrillators (CRT-Ds) \u2013 specific models.  \nManufactured by Boston Scientific.\n\n![ASSET_TAG](#ASSET0)\n\n\u00a0\n\nModels affected by this alert:  \n  \n  * Teligen ICDs model numbers E102, E110, E111, F102, F110 and F111.  \n  * Cognis CRT-Ds model numbers N106, N107, N108, N118, N119, P106, P107 and P108.  \n  \n## Problem\n\nFor devices implanted subpectorally there are risks of:  \n  \n  * loss of shock therapy  \n  * inappropriate shock therapy  \n  * loss of pacing therapy  \n  * loss of anti-tachycardia pacing.  \n  \nThe manufacturer has established that the bond between the header and case of these specific models can be weakened either from significant forces associated with a subpectoral implant procedure or when a device in a subpectoral position is repeatedly pushed against a rib during contraction of the pectoralis muscle.\n\nThe following factors may have an impact on the risk of failure if affected devices are implanted subpectorally:  \n  \n  * exact location of the patient\u2019s ribs relative to the device  \n  * body size and/or muscle mass of the patient (risk increases for larger or muscular patients)  \n  * activity level and/or occupation of the patient (risk increases for more active patients)  \n  * increased implantation duration.  \n  \nThe manufacturer issued a [Field Safety Notice in December 2009](http://www.mhra.gov.uk/home/ssLINK/CON065534) informing clinicians about this issue.\n\nExtent of the problem  \nThe manufacturer has confirmed that approximately 2,500 affected Teligen and Cognis devices have been distributed on the UK market since these models were released in June 2008. They have estimated that approximately 5% of affected devices are implanted subpectorally worldwide. Devices implanted subcutaneously are not included in this advisory.\n\nTo date the manufacturer has confirmed two (non-UK) reports of device malfunction associated with this issue out of approximately 77,000 devices sold worldwide. Both devices required early replacement (at four and five months post-implant) as they had delivered inappropriate shocks. The manufacturer has not identified a mean time-to-failure for this problem.\n\nIdentifying failed devices  \nThere are no specific tests to identify a weakened header bond.\n\nStandard in-clinic monitoring and troubleshooting steps for lead-related issues (including isometrics and manipulating the pocket while watching for noise on electrograms and/or inappropriate pacing or shock therapy) are recommended but cannot definitely distinguish a loose header from a failed lead or bad connection of the lead.\n\nEvidence of a weakened header bond is not typically visible via X-ray or fluoroscopy. Should this weakening progress to wire fracture and complete separation of the header from the titanium case it may be visible on X-ray or fluoroscopy.\n\nEarly stages of a weakened header bond may only cause subtle lead impedance changes (in the tens or hundreds of ohms), whereas in the later stages there may be a very large change in lead impedance.\n\nIf available, the LATITUDE patient management system may also be helpful for monitoring patients.\n\nAvailability of modified devices  \nThe manufacturer has made manufacturing process changes to strengthen the bond between the header and case. Modified devices are expected to be available in the UK from February 2010.\n\n## Action  \n  \n  * Review records to identify patients with an affected device implanted subpectorally.  \n  * Recall affected patients for baseline measurements within six weeks, giving priority to those who are pacing-dependent or who have not been followed up within the previous three months.  \n  * Consider programming \u2018Daily Measurement Alerts\u2019 for lead impedance to \u2018On\u2019.  \n  * Consider prophylactic replacement of affected devices in high risk patients.  \n  * Remind affected patients to contact their clinic if they receive shocks.  \n  * Follow up affected patients at three-month intervals (as stated in the manufacturer\u2019s instructions for use).  \n  * Avoid subpectoral implantation of these models.  \n  * Report device failures and adverse incidents to Boston Scientific and the MHRA.  \n  \n## Distribution\n\nThis MDA has been distributed to:  \n  \n  * NHS trusts in England (Chief Executives)  \n  * Care Quality Commission (CQC) (Headquarters)  \n  * NHS boards in Scotland (Chief Executives)  \n  * NHS boards and trusts in Wales (Chief Executives)  \n  * Primary care trusts in England (Chief Executives)  \n  \nOnward distribution  \nPlease bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:\n\nTrusts to:  \nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:  \n  \n  * A&E consultants  \n  * A&E departments  \n  * A&E directors  \n  * A&E nurses  \n  * Cardiac laboratory technicians  \n  * Cardiologists  \n  * Cardiology departments  \n  * Cardiology nurses  \n  * Cardiology, directors of  \n  * Cardiothoracic surgery directors  \n  * Clinical governance leads  \n  * Risk managers  \n  \nCare Quality Commission (CQC) (England only) to:  \nThe MHRA considers this information to be important to:  \n  \n  * Care homes providing nursing care (adults)  \n  * Care homes providing personal care (adults)  \n  * Clinics  \n  * Hospitals in the independent sector  \n  * Independent treatment centres  \n  * Private medical practitioners  \n  \nPrimary care trusts to:  \nCAS liaison officers for onward distribution to all relevant staff including:  \n  \n  * General practitioners  \n  \n## Manufacturer Contact\n\nCait Cowley  \nBoston Scientific  \nBreakspear Park  \nBreakspear Way  \nHemel Hempstead  \nHerts HP2 4TZ\n\nTel: 01442 411 673  \nFax: 01442 411 816\n\nEmail: [Cait.Cowley@bsci.com](mailto:Cait.Cowley@bsci.com)\n\n## Feedback\n\nIf you have any comments or feedback on this Medical Device Alert, please email us at [dts@mhra.gsi.gov.uk](mailto:dts@mhra.gsi.gov.uk)\n\n## England\n\nIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number 2009/011/030/081/012.\n\nTechnical aspects  \nJuliet Aharoni or Hazel Randall  \nMedicines\u00a0and Healthcare products Regulatory Agency  \nMarket Towers  \n1 Nine Elms Lane  \nLondon  \nSW8 5NQ\n\nTel: 020 7084 3177/3287  \nFax: 020 7084 3106\n\nEmail: [juliet.aharoni@mhra.gsi.gov.uk](mailto:juliet.aharoni@mhra.gsi.gov.uk) or\u00a0[hazel.randall@mhra.gsi.gov.uk](mailto:hazel.randall@mhra.gsi.gov.uk)\n\nClinical aspects  \nChristopher Brittain  \nMedicines\u00a0and Healthcare products Regulatory Agency  \nMarket Towers  \n1 Nine Elms Lane  \nLondon  \nSW8 5NQ\n\nTel: 020 7084 3126  \nFax: 020 7084 3111\n\nEmail: [christopher.brittain@mhra.gsi.gov.uk](mailto:christopher.brittain@mhra.gsi.gov.uk)\n\nHow to report adverse incidents  \nPlease report via our website: [Reporting adverse incidents involving medical devices](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm).  \nFurther information about CAS can be found on the [Central Alerting System website](https://www.cas.dh.gov.uk/Home.aspx) (external link).\n\n## Northern Ireland\n\nAlerts in Northern Ireland will continue to be distributed via the NI SABS system.\n\nEnquiries and adverse incident reports in Northern Ireland should be addressed to:\n\nNorthern Ireland Adverse Incident Centre (NIAIC)  \nHealth Estates  \nEstate Policy Directorate  \nStoney Road  \nDundonald  \nBelfast  \nBT16 1US\n\nTel: 02890 523 704  \nFax: 02890 523 900\n\nEmail: [NIAIC@dhsspsni.gov.uk](mailto:NIAIC@dhsspsni.gov.uk)\n\n[Northern Ireland Adverse Incident Centre (NIAIC)](http://www.dhsspsni.gov.uk/index/hea/niaic.htm) (external link)\n\nHow to report adverse incidents in Northern Ireland  \nPlease report directly to NIAIC, further information can be found on the [NIAIC website](http://www.dhsspsni.gov.uk/niaic) (external link).  \nFurther information about SABS can be found on the [SABS website](http://sabs.dhsspsni.gov.uk/) (external link).\n\n## Scotland\n\nEnquiries and adverse incident reports in Scotland should be addressed to:\n\nIncident Reporting and Investigation Centre  \nHealth Facilities Scotland  \nNHS National Services Scotland  \nGyle Square  \n1 South Gyle Crescent  \nEdinburgh  \nEH12 9EB\n\nTel: 0131 275 7575  \nFax: 0131 314 0722\n\nEmail: [nss.iric@nhs.net](mailto:nss.iric@nhs.net)\n\n[Health Facilities Scotland - Incident Reporting and Investigation Centre](http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/) (external link).\n\n## Wales\n\nEnquiries in Wales should be addressed to:\n\nDr Sara Hayes  \nSenior Medical Officer  \nMedical Device Alerts  \nWelsh Assembly Government  \nCathays Park  \nCardiff  \nCF10 3NQ\n\nTel: 029 2082 3922\n\nEmail: [Haz-Aic@wales.gsi.gov.uk](mailto:Haz-Aic@wales.gsi.gov.uk)\n", 
  "raw_html": "<div id=\"inner_tab_content\">\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t<h2 class=\"sw\">Device</h2><div class=\"content_section active_content_section\" id=\"Device\">\r\n\t\t\t\t\t\t\t\t<p><span>Teligen implantable cardioverter defibrillators (ICDs) and Cognis cardiac resynchronisation therapy defibrillators (CRT-Ds) &#8211; specific models.<br> Manufactured by Boston Scientific.</span></p><img src=\"#ASSET0\" alt=\"ASSET_TAG\"><p>&#160;</p><p>Models affected by this alert:</p><ul>\r\n\t\t\t\t<li>Teligen ICDs model numbers E102, E110, E111, F102, F110 and F111.</li>\r\n\t\t\t\t<li>Cognis CRT-Ds model numbers N106, N107, N108, N118, N119, P106, P107 and P108.</li></ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Problem</h2><div class=\"content_section\" id=\"Problem\">\r\n\t\t\t\t\t\t\t\t<p><span>For devices implanted subpectorally there are risks of:</span></p><ul>\r\n\t\t\t\t<li><span>loss of shock therapy</span></li>\r\n\t\t\t\t<li><span>inappropriate shock therapy</span></li>\r\n\t\t\t\t<li><span>loss of pacing therapy</span></li>\r\n\t\t\t\t<li><span>loss of anti-tachycardia pacing.</span></li></ul><p>The manufacturer has established that the bond between the header and case of these specific models can be weakened either from significant forces associated with a subpectoral implant procedure or when a device in a subpectoral position is repeatedly pushed against a rib during contraction of the pectoralis muscle.</p><p>The following factors may have an impact on the risk of failure if affected devices are implanted subpectorally:</p><ul>\r\n\t\t\t\t<li>exact location of the patient&#8217;s ribs relative to the device</li>\r\n\t\t\t\t<li>body size and/or muscle mass of the patient (risk increases for larger or muscular patients)</li>\r\n\t\t\t\t<li>activity level and/or occupation of the patient (risk increases for more active patients)</li>\r\n\t\t\t\t<li>increased implantation duration.</li></ul><p>The manufacturer issued a <a href=\"http://www.mhra.gov.uk/home/ssLINK/CON065534\">Field Safety Notice in December 2009</a> informing clinicians about this issue.</p><p><font class=\"h3\">Extent of the problem</font><br>The manufacturer has confirmed that approximately 2,500 affected Teligen and Cognis devices have been distributed on the UK market since these models were released in June 2008. They have estimated that approximately 5% of affected devices are implanted subpectorally worldwide. Devices implanted subcutaneously are not included in this advisory.</p><p>To date the manufacturer has confirmed two (non-UK) reports of device malfunction associated with this issue out of approximately 77,000 devices sold worldwide. Both devices required early replacement (at four and five months post-implant) as they had delivered inappropriate shocks. The manufacturer has not identified a mean time-to-failure for this problem.</p><p><font class=\"h3\">Identifying failed devices</font><br>There are no specific tests to identify a weakened header bond.</p><p>Standard in-clinic monitoring and troubleshooting steps for lead-related issues (including isometrics and manipulating the pocket while watching for noise on electrograms and/or inappropriate pacing or shock therapy) are recommended but cannot definitely distinguish a loose header from a failed lead or bad connection of the lead.</p><p>Evidence of a weakened header bond is not typically visible via X-ray or fluoroscopy. Should this weakening progress to wire fracture and complete separation of the header from the titanium case it may be visible on X-ray or fluoroscopy.</p><p>Early stages of a weakened header bond may only cause subtle lead impedance changes (in the tens or hundreds of ohms), whereas in the later stages there may be a very large change in lead impedance.</p><p>If available, the LATITUDE patient management system may also be helpful for monitoring patients.</p><p><font class=\"h3\">Availability of modified devices<br></font>The manufacturer has made manufacturing process changes to strengthen the bond between the header and case. Modified devices are expected to be available in the UK from February 2010.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Action</h2><div class=\"content_section\" id=\"Action\">\r\n\t\t\t\t\t\t\t\t<ul>\r\n\t\t\t\t<li>Review records to identify patients with an affected device implanted subpectorally.</li>\r\n\t\t\t\t<li>Recall affected patients for baseline measurements within six weeks, giving priority to those who are pacing-dependent or who have not been followed up within the previous three months.</li>\r\n\t\t\t\t<li>Consider programming &#8216;Daily Measurement Alerts&#8217; for lead impedance to &#8216;On&#8217;.</li>\r\n\t\t\t\t<li>Consider prophylactic replacement of affected devices in high risk patients.</li>\r\n\t\t\t\t<li>Remind affected patients to contact their clinic if they receive shocks.</li>\r\n\t\t\t\t<li>Follow up affected patients at three-month intervals (as stated in the manufacturer&#8217;s instructions for use).</li>\r\n\t\t\t\t<li>Avoid subpectoral implantation of these models.</li>\r\n\t\t\t\t<li>Report device failures and adverse incidents to Boston Scientific and the MHRA.</li></ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Distribution</h2><div class=\"content_section\" id=\"Distribution\">\r\n\t\t\t\t\t\t\t\t<p>This MDA has been distributed to:</p><ul>\r\n\t\t\t\t<li>NHS trusts in England (Chief Executives)</li>\r\n\t\t\t\t<li>Care Quality Commission (CQC) (Headquarters)</li>\r\n\t\t\t\t<li>NHS boards in Scotland (Chief Executives)</li>\r\n\t\t\t\t<li>NHS boards and trusts in Wales (Chief Executives)</li>\r\n\t\t\t\t<li>Primary care trusts in England (Chief Executives)</li></ul><p><font class=\"h3\">Onward distribution</font><br>Please bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:</p><p><font class=\"h4\">Trusts to:</font><br>CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:</p><ul>\r\n\t\t\t\t<li>A&amp;E consultants</li>\r\n\t\t\t\t<li>A&amp;E departments</li>\r\n\t\t\t\t<li>A&amp;E directors</li>\r\n\t\t\t\t<li>A&amp;E nurses</li>\r\n\t\t\t\t<li>Cardiac laboratory technicians</li>\r\n\t\t\t\t<li>Cardiologists</li>\r\n\t\t\t\t<li>Cardiology departments</li>\r\n\t\t\t\t<li>Cardiology nurses</li>\r\n\t\t\t\t<li>Cardiology, directors of</li>\r\n\t\t\t\t<li>Cardiothoracic surgery directors</li>\r\n\t\t\t\t<li>Clinical governance leads</li>\r\n\t\t\t\t<li>Risk managers</li></ul><p><font class=\"h4\">Care Quality Commission (CQC) (England only) to:<br></font> The MHRA considers this information to be important to:</p><ul>\r\n\t\t\t\t<li>Care homes providing nursing care (adults)</li>\r\n\t\t\t\t<li>Care homes providing personal care (adults)</li>\r\n\t\t\t\t<li>Clinics</li>\r\n\t\t\t\t<li>Hospitals in the independent sector</li>\r\n\t\t\t\t<li>Independent treatment centres</li>\r\n\t\t\t\t<li>Private medical practitioners</li></ul><p><font class=\"h4\">Primary care trusts to:</font><br>CAS liaison officers for onward distribution to all relevant staff including:</p><ul>\r\n\t\t\t\t<li>General practitioners</li></ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Manufacturer Contact</h2><div class=\"content_section\" id=\"Manufacturer Contact\">\r\n\t\t\t\t\t\t\t\t<p>Cait Cowley<br>Boston Scientific<br>Breakspear Park<br>Breakspear Way<br>Hemel Hempstead<br>Herts HP2 4TZ</p><p>Tel: 01442 411 673<br>Fax: 01442 411 816</p><p>Email: <a href=\"mailto:Cait.Cowley@bsci.com\">Cait.Cowley@bsci.com</a></p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Feedback</h2><div class=\"content_section\" id=\"Feedback\">\r\n\t\t\t\t\t\t\t\tIf you have any comments or feedback on this Medical Device Alert, please email us at <a href=\"mailto:dts@mhra.gsi.gov.uk\">dts@mhra.gsi.gov.uk</a>\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t<h2 class=\"sw\">England</h2><div class=\"content_section\" id=\"England\">\r\n\t\t\t\t\t\t\t\t\t<p>If you are in England, please send enquiries about this notice to the MHRA, quoting reference number <span>2009/011/030/081/012.</span></p><p><font class=\"h4\">Technical aspects<br></font> Juliet Aharoni or Hazel Randall<br>Medicines&#160;and Healthcare products Regulatory Agency<br>Market Towers<br>1 Nine Elms Lane<br>London<br>SW8 5NQ</p><p>Tel: 020 7084 3177/3287<br>Fax: 020 7084 3106</p><p>Email: <a href=\"mailto:juliet.aharoni@mhra.gsi.gov.uk\">juliet.aharoni@mhra.gsi.gov.uk</a> or&#160;<a href=\"mailto:hazel.randall@mhra.gsi.gov.uk\">hazel.randall@mhra.gsi.gov.uk</a></p><p><font class=\"h4\">Clinical aspects</font><br>Christopher Brittain<br>Medicines&#160;and Healthcare products Regulatory Agency<br>Market Towers<br>1 Nine Elms Lane<br>London<br>SW8 5NQ</p><p>Tel: 020 7084 3126<br>Fax: 020 7084 3111</p><p>Email: <a href=\"mailto:christopher.brittain@mhra.gsi.gov.uk\">christopher.brittain@mhra.gsi.gov.uk</a></p><p><font class=\"h3\">How to report adverse incidents</font><br>Please report via our website: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm\">Reporting adverse incidents involving medical devices</a>.<br>Further information about CAS can be found on the <a href=\"https://www.cas.dh.gov.uk/Home.aspx\" target=\"_blank\">Central Alerting System website</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Northern Ireland</h2><div class=\"content_section\" id=\"Northern Ireland\">\r\n\t\t\t\t\t\t\t\t\t<p>Alerts in Northern Ireland will continue to be distributed via the NI SABS system.</p><p>Enquiries and adverse incident reports in Northern Ireland should be addressed to:</p><p>Northern Ireland Adverse Incident Centre (NIAIC)<br>Health Estates<br>Estate Policy Directorate<br>Stoney Road<br>Dundonald<br>Belfast<br>BT16 1US</p><p>Tel: 02890 523 704<br>Fax: 02890 523 900</p><p>Email: <a href=\"mailto:NIAIC@dhsspsni.gov.uk\">NIAIC@dhsspsni.gov.uk</a></p><p><a href=\"http://www.dhsspsni.gov.uk/index/hea/niaic.htm\" target=\"_blank\">Northern Ireland Adverse Incident Centre (NIAIC)</a> (external link)</p><p><font class=\"h3\">How to report adverse incidents in Northern Ireland</font><br>Please report directly to NIAIC, further information can be found on the <a href=\"http://www.dhsspsni.gov.uk/niaic\" target=\"_blank\">NIAIC website</a> (external link).<br>Further information about SABS can be found on the <a href=\"http://sabs.dhsspsni.gov.uk/\" target=\"_blank\">SABS website</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Scotland</h2><div class=\"content_section\" id=\"Scotland\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries and adverse incident reports in Scotland should be addressed to:</p><p>Incident Reporting and Investigation Centre<br>Health Facilities Scotland<br>NHS National Services Scotland<br>Gyle Square<br>1 South Gyle Crescent<br>Edinburgh<br>EH12 9EB</p><p>Tel: 0131 275 7575<br>Fax: 0131 314 0722</p><p>Email: <a href=\"mailto:nss.iric@nhs.net\">nss.iric@nhs.net</a></p><p><a href=\"http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/\" target=\"_blank\">Health Facilities Scotland - Incident Reporting and Investigation Centre</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Wales</h2><div class=\"content_section\" id=\"Wales\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries in Wales should be addressed to:</p><p>Dr Sara Hayes<br>Senior Medical Officer<br>Medical Device Alerts<br>Welsh Assembly Government<br>Cathays Park<br>Cardiff<br>CF10 3NQ</p><p>Tel: 029 2082 3922</p><p>Email: <a href=\"mailto:Haz-Aic@wales.gsi.gov.uk\">Haz-Aic@wales.gsi.gov.uk</a></p>\r\n\t\t\t\t\t\t\t\t</div>\r\n</div>\r\n\t\t\t", 
  "title": "Medical Device Alert: Teligen and Cognis defibrillators - specific models, manufactured by Boston Scientific (MDA/2010/012)", 
  "alert_type": [
    "devices"
  ], 
  "medical_specialism": []
}